Search research articles
Contact Us
Filters
Showing results (61-70 of 148) with videos related to
Page
of 15
Sort By:
Leukemia
|
August 7, 2009
Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
B G M Durie, B Van Ness, C Ramos, et al.
Blood Cancer Journal
|
May 13, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
Brian G M Durie, Antje Hoering, Rachael Sexton, et al.
Clinical Therapeutics
|
July 16, 2018
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
Robert M Rifkin, Sundar Jagannath, Brian G M Durie, et al.
Leukemia & Lymphoma
|
January 15, 2016
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide
Robert M Rifkin, Rafat Abonour, Jatin J Shah, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 31, 2018
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
Sundar Jagannath, Rafat Abonour, Brian G M Durie, et al.
Blood
|
September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Rahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
Blood Advances
|
July 11, 2018
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
Sundar Jagannath, Rafat Abonour, Brian G M Durie, et al.
British Journal of Haematology
|
August 6, 2019
Development of a prognostic model for overall survival in multiple myeloma using the Connect<sup>®</sup> MM Patient Registry
Howard R Terebelo, Rafat Abonour, Cristina J Gasparetto, et al.
Blood Cancer Journal
|
October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
Lia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
Cancer Medicine
|
November 9, 2019
Connect MM Registry as a national reference for United States multiple myeloma patients
Sikander Ailawadhi, Sundar Jagannath, Mohit Narang, et al.
Page
of 15
Search research articles
Search
Showing results (61-70 of 148) with videos related to
Sort By:
Page
of 15
Leukemia
|
August 7, 2009
Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma
B G M Durie, B Van Ness, C Ramos, et al.
Blood Cancer Journal
|
May 13, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
Brian G M Durie, Antje Hoering, Rachael Sexton, et al.
Clinical Therapeutics
|
July 16, 2018
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
Robert M Rifkin, Sundar Jagannath, Brian G M Durie, et al.
Leukemia & Lymphoma
|
January 15, 2016
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide
Robert M Rifkin, Rafat Abonour, Jatin J Shah, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 31, 2018
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
Sundar Jagannath, Rafat Abonour, Brian G M Durie, et al.
Blood
|
September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
Rahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
Blood Advances
|
July 11, 2018
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
Sundar Jagannath, Rafat Abonour, Brian G M Durie, et al.
British Journal of Haematology
|
August 6, 2019
Development of a prognostic model for overall survival in multiple myeloma using the Connect<sup>®</sup> MM Patient Registry
Howard R Terebelo, Rafat Abonour, Cristina J Gasparetto, et al.
Blood Cancer Journal
|
October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
Lia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
Cancer Medicine
|
November 9, 2019
Connect MM Registry as a national reference for United States multiple myeloma patients
Sikander Ailawadhi, Sundar Jagannath, Mohit Narang, et al.
Page
of 15